Longitude Venture Partners L.P.

Longitude Venture Partners L.P. discloses dealings in Corcept Therapeutics Inc to SEC (Form 4). Between 11 November 2008 and 28 November 2016, the trades on record add up to 46 filings.

Both buying and selling appear: 3 purchases worth €6.9M, against 32 sales worth €14.8M. Sales outweigh purchases by €7.9M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 9 share grants. Since January 2016: no purchases and 16 sales on the market.

The median purchase comes to €2.3M. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +5.0%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 30 November 2016, the filings show a transaction in Corcept Therapeutics Inc. The last purchase on record was published on 25 January 2011, which is 5,767 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.